Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
Eligible age
All ages
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Dystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however, the evolution of heart dysfunction is not well-understood. The central objectives of this proposal are to elucidate this evolution of heart dysfunction and identify measures from cardiac MRI images that can predict death or significant heart disease in patients with DMD/BMD/MDC. This study will create a large clinical and cardiac MRI registry of dystrophin associated heart dysfunction, will utilize advanced image analysis techniques, including deep learning neural networks, to comprehensively evaluate every patient, and will create a risk toolkit accessible to clinicians around the world; this proposal has the potential to improve the quality of life in patients with dystrophin associated heart dysfunction by allowing for earlier and more intensive therapy in patients with severe disease and by identifying surrogate outcome measures for use in therapeutic trials.
Sponsor: Vanderbilt University Medical Center
You may qualify if…
- ✓ Clinical phenotype of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or muscular dystrophy carrier (MDC) confirmed with muscle biopsy or genotype
You may not qualify if…
- ✕ Additional genetic or congenital abnormality that may affect cardiovascular function or progression
- ✕ Current investigational therapy that may affect cardiovascular function (would preclude ongoing data collection but prior data would still be used)
Where it's recruiting
Sacramento
Washington D.C.
Chicago
Indianapolis
Durham
Columbus
Nashville
Richmond
Seattle
Source: ClinicalTrials.gov · NCT07674758 · last updated 2026-07-28